Product Datasheet

MRTX1719

Catalog No. **BP-02037** · CAS **2630904-45-7** · Form **free base** · Physical state **other** · Color **White to light yellow** · Version **1.0** · Revision **2026-09-03**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Histone Methyltransferase	**Cancer**

Molecular formula	$C_{23}H_{18}ClFN_6O_2$
Molecular weight	**464.8790**

STRUCTURE



DESCRIPTION

MRTX1719 is a synthetic lethal inhibitor of the PRMT5/MTA complex and selectively inhibits PRMT5 activity.

BIOLOGICAL ACTIVITY

In Vitro

Navlimetostat (10 day) inhibits the PRMT5 activity and in MTAP-deleted HCT116 cells not wild type cells, with the IC50 of 8 nM[1]. Navlimetostat (10 day) inhibits the cell viability of MTAP del HCT116 cells with an IC50 value of 12 nM and parental HCT116 cells with an IC50 value of 890 nM.

In Vivo

Navlimetostat (12.5-100 mg/kg/d for p.o., 21 day) reduces the tumor growth in Lu-99 orthotopic xenograft tumor models.

SOLUBILITY

Soluble in DMSO 100 mg/mL

REFERENCES

[1]. Lars D Engstrom, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer Discov. 2023 Aug 8;CD-23-0669.

[2]. Christopher R Smith, et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022 Feb 10;65(3):1749-1766.